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INTRODUCTION
Liver biopsy evaluation was the foundation for the proposals that certain individuals who do not consume excess
alcohol could, in fact, suffer from a form of chronic progressive liver disease characterized by lesions that had been
considered those of alcohol, namely, steatosis, ballooned
hepatocytes with Mallory-Denk hyaline bodies, and the
particular form of fibrosis of alcohol. Several authors
had been evaluating this concept[1-5], when the seminal
manuscript of Ludwig et al[6] was published in 1980 that
described 20 subjects. Since that time, much of the progress that has been made in studies of natural history[7-12],
clinical associations of histological assessments of activity
and fibrosis, correlations with metabolic syndrome[13,14]
and serum markers of cardio-vascular disease[15], the variability of ethnic susceptibility[16-18], and the presence of
hepatocellular carcinoma in cirrhotics and non-cirrhotics
with nonalcoholic fatty liver disease (NAFLD)[19-21] have
occurred by evaluating liver biopsies.
The clinical and scientific needs for imaging studies and serum-based assays to “predict” the presence of
steatohepatitis, fibrosis, and/or inflammation are based
on a well-recognized concept that liver biopsy is invasive,
potentially harmful, and may suffer from “sampling error”[22,23]. Furthermore, liver biopsy cannot be considered

Abstract
Histological analysis of liver biopsies remains a standard against which other methods of assessment for
the presence and amount of hepatic injury due to
nonalcoholic fatty liver disease (NAFLD) are measured.
Histological evaluation remains the sole method of distinguishing steatosis from advanced forms of NAFLD,
i.e. nonalcoholic steatohepatitis (NASH) and fibrosis.
Included in the lesions of NAFLD are steatosis, lobular
and portal inflammation, hepatocyte injury in the forms
of ballooning and apoptosis, and fibrosis. However,
patterns of these lesions are as distinguishing as the
lesions themselves. Liver injury in adults and children
due to NAFLD may have different histological patterns.
In this review, the rationale for liver biopsy, as well as
the histopathological lesions, the microscopically observable patterns of injury, and the differential diagnoses of NAFLD and NASH are discussed.
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a screening tool for population studies. However, it is also
recognized that, imperfect as it is, liver biopsy evaluation
remains the standard against which other assays and clinical algorithms must be matched, and prospectively validated.
Liver biopsy does, indeed, suffer from challenges.
Many can be overcome by the realization that even an adequate biopsy represents only 1/50 000-1/65 000 of this
large organ. Therefore, high quality biopsy techniques,
such as utilization of appropriately sized needles[24], careful choice of sampled area, and appropriate tissue preparation and interpretation are all important considerations
for liver biopsy. Pathologists recognize that wedge biopsies are inferior to appropriately-sized and placed needle
core biopsies for evaluation of a diffuse parenchymal
disease. In addition, there might be differences between
right and left lobes of the liver, as the left lobe is relatively
smaller, is covered by more capsule per unit area, and the
subcapsular portal tracts can be deceptively more fibrous
than those of deeper parenchyma. Differences in histopathological findings have been demonstrated in studies
of bariatric patients biopsied concurrently from the right
and left lobes[25]; these differences were abrogated somewhat by the use of a large bore needle in another study[24].
Adequate sample length has also been noted as a correlative factor with histological evaluation in NAFLD[26], with
biopsies ≥ 1.5 cm long having a higher yield of definitive
nonalcoholic steatohepatitis (NASH) diagnosis compared
to those measuring < 1 cm in length (29% vs 56%)[26].
Small biopsies (< 1.6 cm) show higher variability for
NAFLD fibrosis stage than longer biopsies[27]. It has been
proposed that sampling error might be reduced by using
larger gauge needles[24], obtaining longer (≥ 1.5 cm) biopsies[28], or by taking more than one tissue core when possible[26]. Once in the laboratory, liver biopsies should not
be prepared on tissue “sponges”, as these create spacedistorting artifacts[29]. Of at least equal, if not greater,
significance, however, is pathologists’ training and focus
in the field. Just as one doesn’t ask a non-specialized surgeon to perform cardiac bypass surgery, one should also
recognize the need for trained liver pathologists. Studies
in chronic hepatitis C (CHC) liver biopsy evaluation that
compared the expertise of liver pathologists in academic
practice with community pathologists showed this to be
a potential source of discordance in histological evaluation[30]. The number of independent readings has also
been shown to correlate with greater yield of findings[26].

were either “normal” (6%) or had histopathological features of subsequently clinically confirmed liver disease,
such as hereditary hemochromatosis, drug-induced liver
injury, and autoimmune liver disease. Several series have
now shown the lack of correlation of alanine aminotransferase (ALT) levels and both necroinflammatory activity
and fibrosis, including cirrhosis, in subjects with known
NAFLD[32-34], including obese children[35]. Liver biopsy
evaluation is also important for a patient with a clinical
suspicion of autoimmune liver disease. Up to 20% of
NAFLD have positive serologies for antinuclear antibody,
antismooth muscle antibody, and/or antimitochondrial
antibody[36-38]; therefore, liver biopsy evaluation might be
the only means of determining the underlying cause of
the disease. Furthermore, surgeons have shown that intraoperative visualization is commonly not correct for the
prediction of either steatosis or advanced fibrosis, and thus
liver biopsy is currently being recommended in the morbidly obese bariatric population at the time of surgery[39].
The final “pro” of liver biopsy is both confirmation
of the diagnosis, as well as evaluation and semiquantitation of necroinflammatory lesions and fibrosis, and
evaluation of architectural remodeling. To date, noninvasive tests have shown to be effective for the extremes:
either lack of, or abundance of, inflammation or fibrosis,
but overall sensitivity and specificity for the lesions in
between are less impressive[22]. A recently studied modification of the European Liver Fibrosis score, named
the Enhanced Liver Fibrosis score, has shown the most
promise in terms of predicting over 75% of adult patients who would not need a liver biopsy, regardless of
stage[40]. Measurement of serum keratin 18 (K18) fragments, a marker of hepatocyte apoptosis, has emerged
as a promising biomarker for NASH, with sensitivity
and specificity of up to 77% and 92%, respectively[41].
Transient elastography measuring liver stiffness has been
recently shown to be a useful noninvasive test to exclude
advanced fibrosis in Chinese NAFLD patients, with a
negative predictive value of 97% [42]. Limitations and
need for further testing of this modality are reviewed[43].
The arguments against liver biopsy in NAFLD include the invasive nature of the procedure, the lack
of effective treatments beyond recommendations for
dietary changes, weight loss and exercise, the fact that
only a minority of NAFLD patients have the progressive lesions of NASH[44], and the known improvements
of diagnosis with clinically-derived tests[45,46] and imaging
techniques[47]. However, at present, the final correlation
for any of the new tests is liver biopsy evaluation.

VALUE OF LIVER BIOPSY EVALUATION
IN NONALCOHOLIC FATTY LIVER
DISEASE

HISTOLOGY OF NAFLD IN ADULTS
The histological spectrum of NAFLD includes various
forms of small and large droplet macrovesicular steatosis, with or without lobular and portal inflammation,
and steatohepatitis, which is characterized by steatosis,
inflammation, and cell injury, i.e. NASH. Progression
of fibrosis and architectural remodeling is thought to
develop in 10%-15% of NASH patients, and cirrhosis

Pro’s and Con’s of liver biopsy
The large series of over 350 liver biopsies done for clinically unexplained liver test elevation in adults by Skelly
et al[31] highlights the value of liver biopsy evaluation in this
setting. While two-thirds of the biopsies showed some
form of nonalcoholic fatty liver disease, the remainder
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in 15%-25%. Thus, of all individuals with some form(s)
of fatty liver, 3%-5% may develop cirrhosis[48]. Cirrhosis
due to NASH and cryptogenic cirrhosis might both result in hepatocellular carcinoma (HCC)[19,49]. Rarely, HCC
may occur in non-cirrhotic NASH[21,50].

pale cytoplasm and, usually, show a large, hyperchromatic
nucleus, often with a prominent nucleolus. They might
be the result of alterations in intermediate filament cytoskeleton[61] and/or presence of microvesicular steatosis[62].
The histological recognition of hepatocellular ballooning
can show significant inter-observer variation[63]. Loss of
the normal hepatocyte keratins, 8 and 18, as detected by
immunostaining, might help in the objective identification
of ballooned hepatocytes[64].
Apoptotic (acidophil) bodies, another form of hepatocyte injury and a feature of programmed cell death,
are common in NASH[65]. They can easily be identified
on routine stains, but are further highlighted by immunohistochemistry for keratin 18 fragments, the same antigen that has been recently proposed as a biomarker of
NASH[41,66]. The number of acidophil bodies per mm2 of
liver tissue (acidophil body index) has been proposed to
serve as a complementary histological feature when diagnosis of NASH is uncertain[67].
Lobular inflammation is usually mild, and consists of a
mixed inflammatory cell infiltrate, composed of lymphocytes, some eosinophils, and, occasionally, a few neutrophils. Polymorphs are occasionally observed surrounding
ballooned hepatocytes in a lesion known as “satellitosis”.
Foci of chronic lobular inflammation, consisting mainly
of lymphocytes, are occasionally seen. Scattered lobular
microgranulomas (Kupffer cell aggregates) and lipogranulomas are common[57,68].
Portal chronic mononuclear cell inflammation in adult
NASH is not uncommon and is usually mild. When severe
or disproportionate to the acinar lesions, the possibility of
concurrent CHC should be excluded[56,68,69]. In untreated
NAFLD patients, increased portal inflammation has been
proposed as a marker of severe disease[70], and has been
correlated with the diagnosis of definite steatohepatitis[71].
Fibrosis in adult NASH usually starts in acinar zone 3
and has a characteristic “chicken wire” pattern due to deposition of collagen and other extracellular matrix fibers
along the sinusoids of zone 3 and around the hepatocytes.
Portal fibrosis without perisinusoidal/pericellular fibrosis
has been reported in some cases of morbid obesity-related NASH[72,73] and in pediatric NASH (discussed below).
In advanced disease, bridging fibrosis and cirrhosis might
develop[51]. NASH-related cirrhosis is most commonly
macronodular or mixed. At the cirrhotic stage, perisinusoidal fibrosis and other features of “active” disease may
or may not be evident. Therefore, in the absence of a previous biopsy with NASH or other disease-specific histology, the cirrhosis may be labeled “cryptogenic”. In a recent
meta-analysis of ten longitudinal histological studies of
NASH, presence of inflammation in the initial biopsy and
age emerged as independent predictors of progression to
advanced fibrosis in patients with NASH[74].
Sinusoidal collagen formation in NASH, as in other
chronic liver diseases, is likely to be the result of hepatic
stellate cell (HSC) activation[75,76]. The HSC activation
score, as measured by alpha-smooth muscle actin immunohistochemistry, was shown to predict progression
of fibrosis in NAFLD[77]. Portal fibrosis, on the other

NAFLD
The main histological characteristic of NAFLD, as its
name implies, is the accumulation of fat in the form of
triglycerides within hepatocytes, a lesion originally termed
“steatosis” after the ancient Greek word for fat, “stear”.
The presence of > 5% steatotic hepatocytes in a liver tissue section is now accepted as the minimum criterion for
the histological diagnosis of NAFLD[51,52].
Steatosis in NAFLD is usually macrovesicular, referring to hepatocytes with a single large intracytoplasmic fat
droplet or smaller well defined droplets displacing the nucleus to the cell periphery. Mixed steatosis might also occur, when, in addition to macrovesicular steatosis, groups
of hepatocytes with centrally placed nuclei and numerous
minute lipid droplets in the cytoplasm are observed. Pure
microvesicular steatosis, needing special stains such as OilRed-O to identify the intracytoplasmic material as fat, is
not a common feature of NAFLD; however, small, azonal
collections of hepatocytes might have this type of fat. In
simple NAFLD, in addition to steatosis, foci of lobular
inflammation, mild portal inflammation, and lipogranulomas may be seen. However, features of hepatocellular injury and fibrosis, indicating progression to steatohepatitis,
are not observed, by definition[51].
The extent of steatosis is commonly evaluated and reported semi-quantitatively. The most reproducible method
follows the acinar architecture dividing the liver parenchyma in thirds and assessing percentage involvement by
steatotic hepatocytes: 0%-33% (or 0%-5%, 5%-33%)-mild,
33%-66%-moderate or > 66% - severe steatosis[53,54].
One of the distinctive features of steatosis in adult
NAFLD, in contrast to most pediatric NAFLD cases, is its
predilection to start in acinar zone 3 (perivenular). When
steatosis is severe it can occupy the whole acinus. Steatosis
might not persist during the progression of fibrosis to
remodeling and cirrhosis; thus, steatosis might not be reliably identified in a cirrhotic liver[55].
Adult NASH
Most hepatopathologists agree that the minimal criteria
for the histological diagnosis of adult NASH include steatosis, hepatocyte injury, usually in the form of ballooning, and lobular inflammation, typically localized in acinar
zone 3. Fibrosis, as in other forms of chronic hepatitis, is
not a required diagnostic feature of NASH[56-58].
Hepatocellular injury in NASH can take the form of
ballooning, apoptosis, or lytic necrosis[51]. Ballooning is a
feature of major importance in NASH as its presence has
been associated in prognostic studies with more aggressive
disease and high incidence of cirrhosis[59]. Furthermore,
the presence of ballooned hepatocytes on liver biopsy has
been linked with features of the metabolic syndrome[60].
Ballooned hepatocytes are enlarged, with swollen, rarefied,
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ogists is lobular inflammation[54,88,89]. Intra-observer agreement is generally better than inter-observer agreement for
all histological features and diagnostic categories.

hand, has been linked to the ductular reaction (i.e. ductular proliferation at the portal tract interface arising from
progenitor cells in the periportal area and accompanied
by neutrophils and stromal changes). These findings have
been correlated with insulin resistance, impaired hepatocellular replication, and advanced stages of fibrosis,
indicating that it might provide a pathway for progressive
fibrosis[78]. Recent work has found evidence of epithelialto-mesenchymal transition of ductular cells via activation
of the hedgehog pathway, a process by which mature
epithelial cells differentiate into cells with a mesenchymal
phenotype and function, in NAFLD[79].
Other histological lesions that may be seen in NASH
include Mallory-Denk bodies (MDB), megamitochondria,
glycogenated nuclei, and iron deposition. MDB (previously
called Mallory bodies or Mallory’s hyaline)[61] are eosinophilic intracytoplasmic inclusions commonly seen close to
the nucleus of ballooned hepatocytes in zone 3, usually
in areas of perisinusoidal fibrosis. They are composed of
misfolded intermediate filaments (keratins 8 and 18), ubiquitin, heat shock proteins, and p62[80]. MDB have been
correlated with increased necroinflammatory activity[53]
and with a higher incidence of cirrhosis[59]. Although not
a requirement for the histological identification of NASH,
the presence of MDB strengthens the diagnosis. MDB are
not, however, restricted to NASH and can be seen in steatohepatitis due to other causes (alcoholic, drug-induced,
etc), as well as in chronic cholestasis, metabolic diseases,
and hepatocellular neoplasms[81].
Megamitochondria (giant mitochondria) are round or
needle-shaped, eosinophilic, intracytoplasmic inclusions
more commonly observed in hepatocytes with microvesicular steatosis. The are not zonally restricted[82]. Ultrastructural studies have shown that these abnormal mitochondria show loss of cristae, multilamellar membranes,
and paracrystalline inclusions[82,83]. Megamitochondria in
NASH may be the result of injury from lipid peroxidation
or represent an adaptive change[84]. Glycogenated nuclei
are vacuolated nuclei usually observed in periportal hepatocytes. Their presence in biopsies with steatohepatitis
is supportive of nonalcoholic etiology (obesity and/or
diabetes) because they are very rarely seen in biopsies of
alcoholic steatohepatitis (ASH)[85].
Finally, hepatic siderosis might be seen in NAFLD
biopsies. It is usually mild (1+, 2+) and occurs in periportal hepatocytes and/or pan-acinar reticulo-endothelial
cells. The significance of liver tissue iron deposition and
abnormal iron metabolism genetics in the pathogenesis
and progression of NAFLD are under investigation[86,87].

HISTOLOGICAL FINDINGS OF NAFLD/
NASH IN CONCURRENCE WITH OTHER
LIVER DISEASE
The increased frequency of NAFLD in the general population makes it important for pathologists to recognize the
lesions, especially those of NASH, when concurrent with
other clinically suspected liver diseases. The frequency of
co-existent NASH in a series of > 3000 non-allograft liver
biopsies undertaken for clinical suspicion of CHC, autoimmune hepatitis, hemochromatosis, alpha-1-antitrypsin
deficiency, or chronic hepatitis B was 2.6%[90]. This number most likely underestimates the actual prevalence of
the concurrence given the very stringent criteria for the
diagnosis of SH used in the study[56]. Other groups, however, have found similar results[91].
In CHC, which is the most common chronic liver disease diagnosed with concomitant NASH (5%-10%)[90-93],
the presence of NAFLD can accelerate disease progression and decrease response to antiviral treatment with
negative consequences on patients’ prognoses[94,95]. Other
studies have shown that co-existent fatty liver or NASH in
CHC, more common in patients with genotype 3, was not
related to metabolic disturbances[93]. In a subsequent study,
however, this same group showed that insulin resistance
was increased in CHC, particularly genotypes 1 and 4, and
was independently related to advanced fibrosis[94]. Thus,
the data for CHC and NAFLD is still under investigation.
The diagnosis of concurrent NASH can be a challenge. One study required the identification of the characteristic zone 3 perisinusoidal fibrosis[90], as this is not
a typical finding in other forms of chronic liver disease;
another study only required the prominence of steatosis
and inflammation in zone 3, along with hepatocellular
ballooning[93]. It is important to understand that hepatocellular ballooning, steatosis, and even MDB, have been
documented in CHC[96].
Recently, the co-existence of NAFLD and alcoholic
liver disease (ALD) has been increasingly recognised in
clinical settings. The presence of NAFLD in alcoholic patients has been linked with progression of ALD[97], while
some have shown that moderate alcohol consumption is
associated with fibrosis progression in NAFLD[98]. Interestingly, in contrast, several studies have shown a beneficial effect of moderate alcohol intake. Moderate alcohol
use was shown to be protective against insulin resistance
in morbidly obese individuals[73], was associated with decreased prevalence of fatty liver in asymptomatic individuals[99], and with decreased prevalence of steatohepatitis in
NAFLD patients[100]. The pathologist is not able to recognize the relative contributions of NAFLD or ALD to the
liver injury in a biopsy with steatohepatitis.

HISTOLOGY OF NAFLD IN ADULTS:
PATHOLOGIST REPRODUCIBILITY
Reproducibility studies have shown excellent to good
agreement for the extent of steatosis, presence of perisinusoidal fibrosis, and stage of fibrosis in adult NAFLD;
the feature with the least agreement between histopathol-
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subsequent clinicopathological series from children from
a single site in Rome[112], as well as multiple centers across
North America[115], have found types 1 and 2 less common
than overlap patterns, and individual features such as zone
3 steatosis, ballooning, and zone 3 perisinusoidal fibrosis
less common in children than in adults[121]. However, no
author has yet specified the features and/or patterns of
injury that would result in an unequivocal diagnosis of
“steatohepatitis” in pediatric cases if there were changes
other than the adult-pattern. Thus, this is an area of ongoing investigation in pathology. In addition, there are
no natural history studies to date showing evolution of
the pediatric pattern in children; whether it evolves to the
adult pattern with increasing age or not is unknown. The
rate and processes involved in progression to cirrhosis, an
unfortunate but growing problem[114] in obese children,
are also unknown.

HISTOLOGICAL FINDINGS OF
RESOLUTION OF NASH
Resolution of the histological lesions of NASH is one
of the primary end-points of many treatment trials. It is
now apparent that “spontaneous” resolution of liver injury can occur without treatment (i.e. studies of placebo
groups)[101-103]. This observation, therefore, indicates the
need for adequate sample size as well as randomized
controlled trial for treatment trials of NASH.
Improvement of the major histological features of
disease activity (i.e. steatosis, lobular inflammation, and
ballooning), grade of steatohepatitis and, occasionally, of
fibrosis following therapy using different agents, including
thiazolidinediones (pioglitazone and rosiglitazone), metformin, vitamins E and C, dietary interventions, or bariatric
surgery have been reported[104]. However, after discontinuation of medical treatment, the initial histological improvement might not be maintained, indicating the need for
longer (permanent?) duration of therapy[105]. Nevertheless,
the results of one long-term treatment trial with the insulin
sensitizer roziglitazone showed that there is no additional
anti-steatogenic effect with longer treatment, despite an increase in insulin sensitivity[106]. In contrast, reportedly, surgical intervention for obesity appears to have long-lasting
beneficial effects on liver histology[107,108].
Histological evaluation of post-treatment liver biopsies in a small trial[102] showed that increased portal
inflammation is a feature related to resolution of NASH;
a subsequent review of published treatment trials has confirmed this finding, which is independent of the type of
therapeutic intervention (medical, dietary, or surgical)[56].
In some cases, successful treatment with resolution is associated with the change in the quality of zone 3 perisinusoidal fibrosis from dense to delicate[102].

HISTOLOGY OF NAFLD IN SPECIAL
POPULATIONS
Asians
It is recognized that the body habitus of individuals of
Asian descent differs from that of Caucasoids; there is
greater body fat for a given body mass index (BMI) in
Asians[122], thus, the prevalence and incidence of NAFLD
and advanced fibrosis are related to factors other than
BMI. However, histological features, as described, do
not appear to differ from those described for Caucasian
adults.
Bariatric patients
To date, there is no dedicated literature related to the bariatric population, other than straightforward observations
of changes of steatosis, inflammation, and fibrosis following surgery. Many studies are done without a specific
protocol requiring follow-up biopsies, and most workers
do not require pre and post biopsies to be obtained from
the same lobe of the liver, or for surgical biopsies to be
obtained as early as possible in the operation to avoid
the accrual of polymorphonuclear leukocytes within the
lobules (i.e. surgical hepatitis). The former is important
because of potential differences between the lobes (capsule: parenchyma ratio) and the latter for obtaining correct lobular inflammation scores. The extant literature is
reviewed[108] and highlights the fact that the majority of
bariatric patients have varying amounts of steatosis. In addition, a recent study of surgeon ability to detect steatosis
and/or cirrhosis has shown that this is not reproducible;
thus reinforcing the need for liver biopsy in all bariatric
patients[123]. To this, the authors would add unpublished
personal observations of the non-cirrhotic biopsies from
bariatric surgery, that (1) it is common to see enlarged,
prominent portal tracts from biopsies obtained from the
left lobe; (2) steatosis is commonly mild and often not in
zone 3; and (3) zone 3 perisinusoidal fibrosis is uncommon. It is possible that the very low calorie diet that commonly precedes the actual surgical procedure influences

HISTOLOGY OF NAFLD IN PEDIATRIC
SUBJECTS
Diagnosis of nonalcoholic fatty liver disease in children
continues to be a challenge for pathologists. Clinicopathological studies have confirmed that the lesions may
or may not resemble those of adults, including cirrhosis
with and without steatosis and inflammation[109-119].
Utilizing a mathematic algorithm of the lesions following evaluation of 100 obese children and their liver biopsies, Schwimmer et al[120] proposed the currently utilized
schema of types 1 and 2 steatohepatitis in pediatric fatty
liver disease. Type 1, the least common overall, but the
most common in girls, resembles the adult pattern, with
zone 3 accentuation of steatosis. Type 2 is more common
in boys, and consists of either zone 1 accentuation of
steatosis, or panacinar steatosis. Ballooning was uncommon in both types. Zone 3 perisinusoidal fibrosis was
uncommon in type 2, whereas, when fibrosis was present, only portal-based fibrosis was seen. A small percent
of cases did not fit completely into either category in the
Schwimmer study, and were referred to as “overlap”. A
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NAFLD and even NASH that may have been present.
Finally, a large European study has shown that after five
years, if insulin resistance has not improved, fibrosis
might actually show progression[124].

lesions, alcoholic foamy degeneration (zone 3 microvesicular steatosis), and cholestasis[51]. Generally, there is
consensus that the overall histopathological appearance of
NASH is milder than that observed in ASH[145], with the
understanding that alcoholic steatosis can be as “mild” as
NAFLD.
Certain histological lesions, including severe steatosis, glycogenated nuclei, and lipogranulomas, are more
frequent in NAFLD compared to ALD; however, their
utility in differential diagnosis on an individual basis is limited[145]. On the other hand, numerous, well formed MDB
and dense fibrosis, composed mostly of collagen type Ⅲ
might be indicative of an alcoholic rather than metabolic
origin[146-148]. One group utilized immunohistochemical
detection of the insulin receptor (IR) and increased expression of protein tyrosine phosphatase 1B (PTP1B), a
protein that acts as a negative regulator of IR expression,
to aid in the histological distinction of ASH and NASH.
IR receptor was more frequent in NASH in contrast to
normal expression for IR in conjunction with low level
expression of PTP1B noted in ASH[149]. The clinical utility
of this method, however, has not been tested. The same
group also proposed a noninvasive model for the differential diagnosis between ALD and NAFLD using the ALD/
NAFLD Index (ANI). This is based on the mean corpuscular volume, aspartate aminotransferase (AST)/ALT
ratio, BMI and gender. An ANI greater than 0 indicates
ALD, while ANI less than 0 is diagnostic of NAFLD[150].
There has been no published validation of this test.

NASH IN THE TRANSPLANTED LIVER
NAFLD can occur in the allograft liver as recurrence or
as a de novo process[125-136].
The incidence of recurrent steatosis in patients transplanted for cryptogenic cirrhosis or NASH-cirrhosis
ranges from 25%-100%, while NASH development is
observed in 10%-37.5% of these cases without leading to
early allograft failure (reviewed in[135]). Recurrent NASH
can progress to advanced fibrosis and cirrhosis, but only
rare cases have been re-transplanted as a result of decompensation due to severe NASH in the allograft[137].
Development of de novo steatosis and/or NASH in the
liver allograft might be the result of metabolic disturbances, as transplanted patients are at increased risk for obesity,
diabetes, hypertension, and hypercholesterolemia and have
decreased physical activity levels. Moreover, anti-rejection
medications, in particular steroid treatment and cyclosporine, are known risks for fatty liver development in the allograft, probably by affecting diabetogenic pathways[51,138].
Therefore, the occurrence of NASH in an allograft liver
of a patient transplanted for “cryptogenic cirrhosis” does
not justify attribution of the original disease to “burnedout” NASH without appropriate clinico-pathological correlation[139-141].

GRADING AND STAGING OF THE
HISTOLOGICAL LESIONS IN NAFLD

DIFFERENTIAL DIAGNOSIS
Clinico-pathological correlation is essential for highlighting the underlying cause of steatohepatitis in a liver biopsy, as the histology is similar irrespective of etiology.
The differential diagnoses of NAFLD and NASH include
ASH, drug toxicity (tamoxifen, glucocorticoids, and highly
active antiretroviral therapy in human immunodeficiency
virus patients), metabolic diseases (such as Wilson disease,
tyrosinemia, and citrin deficiency), lipodystrophy, surgical
procedures (such as jejunoileal bypass and biliopancreatic
diversion), total parenteral nutrition, and malnutrition[51].

The first system for grading necroinflammatory activity and staging fibrosis in NASH appeared in 1999[53] in
response to the growing need for standardization of the
histological criteria used for the diagnosis of NASH and
its differentiation from steatosis, and to meet the necessity
for the development of a histological scoring system similar to those already used for other forms of chronic hepatitis. In this scoring system, the features that were shown
to contribute the most to the severity of the disease, such
as steatosis, lobular and portal inflammation, and hepatocellular ballooning were semi-quantitatively assessed
to produce a three-tier global grade of activity (Table 1).
Staging was based on the characteristic pattern and evolution of fibrosis in NASH with initial involvement of
perisinusoidal spaces in zone 3 (stage 1) and subsequent
development of portal/periportal fibrosis (stage 2), bridging fibrosis (stage 3), and cirrhosis (stage 4) (Table 1)[53].
Among subsequently published scoring systems
for grading histological activity in NAFLD [54,151] and
NASH[152], the current most widely used histological scoring system is the one published in 2005 by the NASH
Clinical Research Network (CRN), sponsored by the
National Institute of Diabetes, Digestive and Kidney Diseases[54]. The NASH CRN system has several advantages:
it is a validated system created from blinded reviews by
nine pathologists, it is applicable to the entire histological

ASH vs NASH
The ongoing discussions of the limits of alcohol intake in “nonalcoholic” fatty liver[142] revolve around the
complex interactions of host (genetic and metabolic)
factors[143,144], the type of alcohol utilized, patterns of
drinking[144], and the potentially beneficial interactions of
modest alcohol with insulin resistance[73].
Hepatopathologists agree that the histology of uncomplicated NAFLD and alcoholic steatosis are indistinguishable. Further, NASH might be indistinguishable
from ASH; however, there are some histological features
observed in ALD that have not yet been described in
NAFLD. These include sclerosing hyaline necrosis (a
combination of dense perivenular fibrosis, MDB accumulation, and hepatocyte necrosis in zone 3), veno-occlusive
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[53,54]

Table 1 Grading activity and staging fibrosis in nonalcoholic steatohepatitis according to Brunt et al (adapted from

Grade 1 (mild)
Grade 2 (moderate)
Grade 3 (severe)

Steatosis (1: ≤ 33%,
2: 33%-66%,
3: ≥ 66%)

Ballooning (zonal location and
severity recorded)

1-2
2-3
2-3

Minimal, zone 3
Present, zone 3
Marked, predominantly zone 3

)

a

Inflammation
L-Lobular [(0-3): 0: absent,
1: < 2, 2: 2-4, 3: > 4 foci]

P-Portal [(0-3): 0: absent,
1: mild, 2: moderate, 3: severe]

L = 1-2
L = 1-2
L=3

P = 0-1
P = 1-2
P = 1-2

a

Counted in 20 × fields. Stage of fibrosis: 1: Zone 3 perisinusoidal fibrosis, focal or extensive; 2: As above with focal or extensive periportal fibrosis; 3:
Bridging fibrosis; 4: Cirrhosis, probable or definite.

Table 2 Nonalcoholic steatohepatitis Clinical Research Network system for scoring activity and fibro[54]
sis in nonalcoholic fatty liver disease (modified from )
Steatosis grade (S)
0: < 5%
1: 5%-33%
2: 34%-66%
3: > 66%

a

Lobular inflammation (L)

Hepatocyte ballooning (B)

0: None
1: < 2
2: 2-4
3: > 4

0: None
1: Few ballooned cells
2: Many ballooned cells

a

Counted in 20 × fields. Nonalcoholic fatty liver disease Activity Score: S + L + B (range 0-8). Stage of fibrosis (Fibrosis
score): 0: None; 1: 1a, mild, zone 3 perisinusoidal fibrosis, 1b, moderate, zone 3 perisinusoidal fibrosis, 1c, portal/
periportal fibrosis only; 2: Zone 3 perisinusoidal fibrosis and portal/periportal fibrosis; 3: Bridging fibrosis; 4: Cirrhosis,
probable or definite.

patients with NAFLD[41], indicate that the currently used
systems could be improved by including these histological
features in the semi-quantitative histological scoring of
both adult and pediatric NAFLD[58].

spectrum of NAFLD, it scores both adult and pediatric
NAFLD biopsies, and it generates a numeric score for
grading activity and NAFLD activity score (NAS) for
comparing pre- and post-treatment biopsies in therapeutic
trials. The NAS derives from the summation of individual
scores for steatosis, lobular inflammation, and hepatocellular ballooning and ranges from 0 to 8 (Table 2). In the
validation study, NAS of 1 or 2 corresponded to definitely
not NASH, while a NAS score 5-8 correlated with definite
NASH. Activity scores 3 and 4 were noted in borderline
cases that did not fulfill the pathologists’ criteria for definite NASH. It is important to note, however, that the
numbers generated by NAS were not created to be used
as a substitute for histological diagnosis; properly utilized,
the NAS is applied by the pathologist after reaching final
diagnosis.
Fibrosis scoring with the NASH CRN system is based
on the prototype staging method proposed by Brunt
et al[53], with the difference that stage 1 is further subdivided into three sub-stages to differentiate between delicate
perisinusoidal zone 3 fibrosis (stage 1a), dense perisinusoidal zone 3 fibrosis (stage 1b), and portal fibrosis only
(stage 1c)[54]. NASH CRN stage 1c refers to the pattern
of fibrosis sometimes seen in severely obese patients and
in pediatric NASH (Table 2). The value of histological
scoring systems for grading and staging in NAFLD in
routine practice has not yet been adequately assessed and,
to date, they are mainly used in treatment trials and in
natural history studies. Furthermore, the recognition of
the significance of other histological features associated
with definite NASH and advanced fibrosis, such as portal
chronic inflammation[70], and the proposed use of serum
biomarkers of hepatocyte apoptosis for risk-stratifying
WJG|www.wjgnet.com
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